Abstract
In an open pilot study, the authors tested whether the nonpeptide glycoprotein (GP) IIb/IIIa antagonist tirofiban, a highly effective and selective blocker of platelet aggregation, prevents the transition of ischemic brain tissue into the infarct proper as defined by MRI (perfusion-weighted/T2-weighted) in patients with acute ischemic stroke. The infarct volume (T2 lesion after 1 week) was smaller in treated patients (n = 10) compared with matched control subjects (n = 10; p = 0.029) with similar initial perfusion deficit (TTP-maps). The authors conclude that GP IIb/IIIa antagonists have therapeutic potential in acute stroke therapy.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Brain Infarction / drug therapy*
-
Brain Infarction / pathology
-
Brain Infarction / prevention & control
-
Brain Ischemia / drug therapy*
-
Brain Ischemia / pathology
-
Cerebrovascular Circulation / drug effects
-
Female
-
Humans
-
Magnetic Resonance Imaging
-
Male
-
Middle Aged
-
Pilot Projects
-
Platelet Aggregation Inhibitors / administration & dosage*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
-
Prospective Studies
-
Tirofiban
-
Tyrosine / administration & dosage*
-
Tyrosine / analogs & derivatives*
Substances
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Tyrosine
-
Tirofiban